| BSN Rank:
24 / 10
(What's this?) |
|
Accomplish Score: 1132
|
|
Popularity Score: 36
|
|
# in My Circle: 0
|
|
# in My Org(s): 1582
|
| We'll Post Your CV for Free! |
| |
| |
|
Speaking/Presenting-Abstract/Poster at Mtg: 45 (585 / 0)
|
- Genomic Approach to Drug Development (2000)
- IgE Mediated Hypersensitivity Reaction to Cetuximab (2000)
- High Gene Copy Number of EGFR by FISH in HNSCC (2000)
|
| |
|
Honors and Awards: 15 (150 / 0)
|
-
Fellowship Award for Research in Japan (2009)
-
The Next Generation Award (2008)
-
Impact 2007-2008 recognition (2008)
|
| |
|
Clinical Trial Activity: 0 (0 / 0)
|
|
| |
|
Grant Support: 9 (81 / 0)
|
-
Predictive markers of a combination cetuximab and sorafenib response and toxicity (2009)
-
Insulin-like growth factor I receptor as a therapeutic target in non-small cell lung cancer (2008 - 2009)
-
The role of Human Papilloma Virus in deregulation of microRNAs in head and neck squamous cell carcinoma (2008 - 2009)
|
| |
|
Patents Pending: 0 (0 / 0)
|
|
| |
|
Journal - Editor/Reviewer: 0 (0 / 0)
|
|
| |
|
Peer Reviewed Papers, Books, Chapters: 34 (204 / 0)
|
-
Infusion reactions to monoclonal antibodies for solid tumors: Immunologic mechanisms and risk factors (2009)
-
Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications (2009)
-
Evolution of clinical trials in head and neck cancer (2009)
|
| |
|
Pre/Non Reviewed Papers, Proceedings: 28 (112 / 0)
|
-
Cetuximab sensitivity in head and neck squamous cell carcinoma cell lines based on the HPV status (2009)
-
Survival outcomes by tumor human papillomavirus (HPV) status in stage III-IV oropharyngeal cancer (OPC) in RTOG 0129 (2009)
-
Mass spectrometry profile as a predictor of overall survival benefit after treatment with epidermal growth factor receptor inhibitors in head and neck squamous cell carcinoma. (2009)
|
| |
|
Membership in Professional Societies: 0 (0 / 0)
|
|
| |
|
White Papers: 0 (0 / 0)
|
|
| |
| Registered on BiotechScienceNews: 0 |
How We Rank
